Vertex Pharmaceuticals has secured a reimbursement deal in France for Orkambi (lumacaftor/ivacaftor), the cystic fibrosis drug that England’s National Health Service last month agreed to reimburse after more than three years of disagreement and stalemate in negotiations with the company.
France’s drug pricing body, the Comité économique des produits de santé (CEPS), has approved national reimbursement of Orkambi for CF...







